Literature DB >> 2143548

Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor.

K B Margulies1, P G Cavero, A A Seymour, N G Delaney, J C Burnett.   

Abstract

Atrial natriuretic factor (ANF) is degraded by neutral endopeptidase. We hypothesized that neutral endopeptidase inhibition (NEP-I) increases sodium excretion and that this effect would be potentiated in the presence of an isolated increase in intrarenal ANF. In seven anesthetized dogs, ANF was infused into one renal artery to produce pathophysiologic concentrations in the supplemented kidney while the control kidney received physiologic circulating concentrations of ANF. In the control kidney, NEP-I (SQ 28,603) produced significant increases in urine flow, absolute sodium excretion and fractional sodium excretion while glomerular filtration rate (GFR) remained constant. These renal actions of NEP-I were associated with marked increases in urinary excretion of ANF and cyclic GMP consistent with decreased renal degradation and increased biologic activity of ANF. All of these effects were significantly greater in the supplemented kidney. The present study suggests that NEP-I produces natriuresis which appears to be independent of changes in GFR. In addition, while NEP-I mimics the renal action of pathophysiologic levels of ANF, NEP-I also potentiates the natriuretic effects of pathophysiologic concentrations of ANF as observed in congestive heart failure or hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143548     DOI: 10.1038/ki.1990.168

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

Review 1.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Characterization of neutral endopeptidase 24.11 in dog glomeruli.

Authors:  C Landry; P Santagata; W Bawab; M C Fournié-Zaluski; B P Roques; P Vinay; P Crine
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

3.  Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.

Authors:  M R Wilkins; S L Settle; J E Kirk; S A Taylor; K P Moore; R J Unwin
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

4.  Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.

Authors:  K B Margulies; M A Perrella; L J McKinley; J C Burnett
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  Renal tubular responsiveness to atrial natriuretic peptide in sodium-retaining chronic caval dogs. A possible role for kinins and luminal actions of the peptide.

Authors:  L Legault; P Cernacek; M Levy; E Maher; D Farber
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

6.  Identification and characterization of a neutral endopeptidase activity in Aplysia californica.

Authors:  W Bawab; R S Aloyz; P Crine; B P Roques; L DesGroseillers
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

7.  Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs.

Authors:  M A Perrella; K B Margulies; C M Wei; L L Aarhus; D M Heublein; J C Burnett
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

8.  Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor.

Authors:  Kentaro Ushijima; Hitoshi Ando; Yusuke Arakawa; Kenichi Aizawa; Chisato Suzuki; Ken Shimada; Shu-Ichi Tsuruoka; Akio Fujimura
Journal:  Pharmacol Res Perspect       Date:  2017-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.